Topic Archives: Sarepta (SRPT)

September 19, 2017 / DrKSSMDPhD

Cisco, Chang & Charlie Part 3

Sometimes literary gimmicks backfire. In May 2015, we premiered “Cisco, Chang & Charlie” (sans Oxford comma) as a James Joycean brooding on the letter C, third letter of the alphabet, in three iterations. At the time, three stocks whose names begin with C were vying for attention and prompting questions from readers. The original plan […]

October 28, 2014 / DrKSSMDPhD

Ebola: To Parse, Perchance to Parlay

[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. He chooses his own topics, and his words and opinions are his own.] Careful analysis of Ebola sequences in infected Africans confirms this: the entire present Ebola outbreak emerged as a consequence of one boy in Meliandoua, in eastern Guinea, eating a […]

June 24, 2014 / DrKSSMDPhD

Hepatitis with a C

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. His words and opinions are his own.] In A History of New York, Washington Irving opens chapter VIII thus: ”In which the author and reader…fall into a very grave and instructive discourse.” This may prove to be a more unleavened column than […]

Comments

Gonz on

PAUL MAMPILLY’S 100X – SEASON 3 / Jul 15, 7:10pm

Calc Risk - Thanks for the additional input. I think you are our new Devil Dog. ... Speaking of which does anyone have...

kds3605 on written by reader

Paul Mampilly’s 100x deal / Jan 8, 10:50am

Paul's TM, Sell: SRPT Paul's Secret Portfolio, Buy: EXPC...

swaraj on written by reader

Paul Mampilly’s 100x deal / Nov 7, 11:29am

Can you please share the entry point on SRPT, thank you in advance.....

calculatedrisk on written by reader

Paul Mampilly’s 100x deal / Nov 6, 9:51pm

Hey! Thanks for the New Era Fortunes tip, really appreciate it and will look into BLFS. He still has SRPT, I'll let you ...

swaraj on written by reader

Paul Mampilly’s 100x deal / Nov 6, 4:00pm

Any Idea on SRPT if still on hold or sell, went down big time today, would appreciate the info. Also did subscribe the N...

linling88 on Such A Pleasant Stay / Dec 14, 10:26am

$SRPT #DMD #Exondyl51: FDA can approve, but payers refuse to cover *Analysts track a payer revolt against Sarepta’s...

gard on

What’s 2 b done about the FDA / May 6, 9:35am

I am talking to day about Sarepta . I am long srpt and I am only a small time trader. About $1000 in Serendipity w...

KennyG on The Last Samurai Biotech / May 5, 2:45pm

$TRIL - I'm not so sure that is necessarily a vote of confidence that should make us feel good about TRIL. In that arti...

DrKSSMDPhD on written by reader

The Zed Files / Feb 26, 3:10pm

Summit is a small UK firm planning to IPO in the US. I was pleasantly surprised by what I found researching this one, th...

KennyG on written by reader

The Gain from Pain Mainly Explained: Fire Walk with Me / Oct 27, 8:57am

But there is some bad news for Sarepta (SRPT). Down ~40% in pre-market as FDA is once again requiring additional data o...

newby3867 on written by reader

Hepatitis with a C: Right Now Someone You Know Has It (and Doesn’t Know) / May 29, 3:49am

Hey Anshuman,hope you are doing well. Oncogenix,Prosensa and Sarepta trade on the Nasdaq market.Stock symbols are Oncoge...

karmaswimswami on “This Tiny, Unknown Biotech is About to Unleash Its ‘Holy Grail’ Drug” / Jan 27, 2:40pm

Sarepta (SRPT) has come up for discussion. This is a gnarly company in gnarly situation going after a gnarly disease (D...